Table 1.
Baseline patient characteristics
| Characteristic | Patients (n=26) |
| Age,* years, median (min–max) | 67.5 (48–89) |
| Race/ethnicity | |
| White | 22 (85) |
| Other | 4 (15) |
| ECOG performance status, n (%) | |
| 0 | 23 (88) |
| 1 | 3 (12) |
| Gleason Score, n (%) | |
| 6 | 0 (0) |
| 7 | 5 (19) |
| ≥8 | 20 (77) |
| Unknown | 1 (4) |
| Median PSA,† ng/mL (IQR) | 29.6 (12.2–77.3) |
| Presence of visceral disease, n (%) | 3 (11) |
| Prior local therapies, n (%) | |
| Prostatectomy | 16 (62) |
| Radiation therapy | 13 (50) |
| Prior systemic therapies, n (%) | |
| Docetaxel | 6 (23) |
| Sipuleucel-T | 13 (50) |
| Radium-223 | 4 (15) |
| Bicalutamide | 11 (42) |
| Abiraterone (single-agent) | 14 (54) |
| Enzalutamide (single-agent) | 12 (46) |
| Any next-generation hormonal therapy (NHT) | 19 (73) |
| NHT sequencing/combinations | |
| Abiraterone then enzalutamide | 5 (19) |
| Enzalutamide then abiraterone | 4 (15) |
| Abiraterone plus enzalutamide | 2 (8) |
| Abiraterone plus apalutamide | 2 (8) |
| Median prior systemic therapies, n (IQR) | 3 (2–3) |
*IQR for age is (59, 73).
†PSA is provided for patients who received at least two doses of study treatment and had at least one follow-up visit (n=25).
ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen.